Peripheral muscle abnormalities in cystic fibrosis: Etiology, clinical implications and response to therapeutic interventions

Journal of Cystic Fibrosis

Volumn 16, Issue 5, 2017, Pages 538-552

  Gruet, Mathieu ^a   Troosters, Thierry ^b,c   Verges, Samuel ^d,e  

^a UNIVERSITÉ DE TOULON   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIV GRENOBLE ALPES   (France)

^e INSERM   (France)

Author keywords

Aerobic function; CFTR; Cystic fibrosis; Exercise interventions; Muscle function; Muscle metabolism; Nutritional status

Indexed keywords

ANABOLIC AGENT; CORTICOSTEROID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; VITAMIN;

ARTICLE; BODY MASS; CYSTIC FIBROSIS; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; ENERGY BALANCE; EXERCISE; EXERCISE TOLERANCE; HUMAN; HYPOXEMIA; INFLAMMATION; LEG MUSCLE; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE EXERCISE; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE METABOLISM; MUSCLE STRENGTH; MUSCLE WEAKNESS; NEUROMUSCULAR ELECTRICAL STIMULATION; NONHUMAN; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PERIPHERAL MUSCLE ABNORMALITY; PHYSICAL ACTIVITY; PHYSICAL INACTIVITY; QUALITY OF LIFE; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; COMPLICATION; DISEASE MANAGEMENT; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGY;

ACTIVITIES OF DAILY LIVING; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MANAGEMENT; HUMANS; MUSCLE WEAKNESS; MUSCULAR ATROPHY; QUALITY OF LIFE;

EID: 85014076626     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.02.007     Document Type: Article

References (166)

1. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 1783–1784.
2. Fogarty, A.W., Britton, J., Clayton, A., Smyth, A.R., Are measures of body habitus associated with mortality in cystic fibrosis?. Chest 142 (2012), 712–717.
3. Troosters, T., Langer, D., Vrijsen, B., Segers, J., Wouters, K., Janssens, W., et al. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. Eur Respir J 33 (2009), 99–106.
4. de Meer, K., Gulmans, V.A., van Der Laag, J., Peripheral muscle weakness and exercise capacity in children with cystic fibrosis. Am J Respir Crit Care Med 159 (1999), 748–754.
5. Hebestreit, H., Schmid, K., Kieser, S., Junge, S., Ballmann, M., Roth, K., et al. Quality of life is associated with physical activity and fitness in cystic fibrosis. BMC Pulm Med, 14, 2014, 26, 10.1186/471-2466-14-26.
6. Nixon, P.A., Orenstein, D.M., Kelsey, S.F., Doershuk, C.F., The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 327 (1992), 1785–1788.
7. Pianosi, P., Leblanc, J., Almudevar, A., Peak oxygen uptake and mortality in children with cystic fibrosis. Thorax 60 (2005), 50–54.
8. Hulzebos, E.H., Bomhof-Roordink, H., van de Weert-van Leeuwen, P.B., Twisk, J.W., Arets, H.G., van der Ent, C.K., et al. Prediction of mortality in adolescents with cystic fibrosis. Med Sci Sports Exerc 46 (2014), 2047–2052.
9. King, S.J., Nyulasi, I.B., Bailey, M., Kotsimbos, T., Wilson, J.W., Loss of fat-free mass over four years in adult cystic fibrosis is associated with high serum interleukin-6 levels but not tumour necrosis factor-alpha. Clin Nutr 33 (2014), 150–155.
10. Lamhonwah, A.M., Bear, C.E., Huan, L.J., Kim Chiaw, P., Ackerley, C.A., Tein, I., Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise. Ann Neurol 67 (2010), 802–808.
11. Maltais, F., Decramer, M., Casaburi, R., Barreiro, E., Burelle, Y., Debigaré, R., et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 189 (2014), e15–e62.
12. Sinaasappel, M., Stern, M., Littlewood, J., Wolfe, S., Steinkamp, G., Heijerman, H.G., et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 1 (2002), 51–75.
13. Engelen, M.P.K.J., Schroder, R., Van der Hoorn, K., Deutz, N.E.P., Com, G., Use of body mass index percentile to identify fat-free mass depletion in children with cystic fibrosis. Clin Nutr 31 (2012), 927–933.
14. Bolton, C.E., Ionescu, A.A., Evans, W.D., Pettit, R.J., Shale, D.J., Altered tissue distribution in adults with cystic fibrosis. Thorax 58 (2003), 885–889.
15. Ionescu, A.A., Evans, W.D., Pettit, R.J., Nixon, L.S., Stone, M.D., Shale, D.J., Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis. Chest 124 (2003), 2220–2228.
16. King, S.J., Nyulasi, I.B., Strauss, B.J.G., Kotsimbos, T., Bailey, M., Wilson, J.W., Fat-free mass depletion in cystic fibrosis: associated with lung disease severity but poorly detected by body mass index. Nutrition 26 (2010), 753–759.
17. Engelen, M.P., Schols, A.M., Does, J.D., Wouters, E.F., Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 71 (2000), 733–738.
18. Hanna, R.M., Weiner, D.J., Overweight and obesity in patients with cystic fibrosis: a center-based analysis. Pediatr Pulmonol 50 (2015), 35–41.
19. King, S., Wilson, J., Kotsimbos, T., Bailey, M., Nyulasi, I., Body composition assessment in adults with cystic fibrosis: comparison of dual-energy X-ray absorptiometry with skinfolds and bioelectrical impedance analysis. Nutrition 21 (2005), 1087–1094.
20. Debigare, R., Cote, C.H., Hould, F.S., LeBlanc, P., Maltais, F., In vitro and in vivo contractile properties of the vastus lateralis muscle in males with COPD. Eur Respir J 21 (2003), 273–278.
21. Divangahi, M., Balghi, H., Danialou, G., Comtois, A.S., Demoule, A., Ernest, S., et al. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet, 5, 2009, e1000586.
22. Pinet, C., Cassart, M., Scillia, P., Lamotte, M., Knoop, C., Casimir, G., et al. Function and bulk of respiratory and limb muscles in patients with cystic fibrosis. Am J Respir Crit Care Med 168 (2003), 989–994.
23. Elkin, S.L., Williams, L., Moore, M., Hodson, M.E., Rutherford, O.M., Relationship of skeletal muscle mass, muscle strength and bone mineral density in adults with cystic fibrosis. Clin Sci (Lond) 99 (2000), 309–314.
24. Pinet, C., Scillia, P., Cassart, M., Lamotte, M., Knoop, C., Mélot, C., et al. Preferential reduction of quadriceps over respiratory muscle strength and bulk after lung transplantation for cystic fibrosis. Thorax 59 (2004), 783–789.
25. Dufresne, V., Knoop, C., Van Muylem, A., Malfroot, A., Lamotte, M., Opdekamp, C., et al. Effect of systemic inflammation on inspiratory and limb muscle strength and bulk in cystic fibrosis. Am J Respir Crit Care Med 180 (2009), 153–158.
26. Gruet, M., Decorte, N., Mely, L., Vallier, J.M., Camara, B., Quetant, S., et al. Skeletal muscle contractility and fatigability in adults with cystic fibrosis. J Cyst Fibros 15 (2016), e1–e8.
27. Selvadurai, H.C., Allen, J., Sachinwalla, T., Macauley, J., Blimkie, C.J., Van Asperen, P.P., Muscle function and resting energy expenditure in female athletes with cystic fibrosis. Am J Respir Crit Care Med 168 (2003), 1476–1480.
28. Rosenfeld, M., Davis, R., FitzSimmons, S., Pepe, M., Ramsey, B., Gender gap in cystic fibrosis mortality. Am J Epidemiol 145 (1997), 794–803.
29. Sweezey, N.B., Ratjen, F., The cystic fibrosis gender gap: potential roles of estrogen. Pediatr Pulmonol 49 (2014), 309–317.
30. Olesen, H.V., Pressler, T., Hjelte, L., Mared, L., Lindblad, A., Knudsen, P.K., et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol 45 (2010), 959–965.
31. Dunnink, M.A., Doeleman, W.R., Trappenburg, J.C., de Vries, W.R., Respiratory muscle strength in stable adolescent and adult patients with cystic fibrosis. J Cyst Fibros 8 (2009), 31–36.
32. Barry, P.J., Waterhouse, D.F., Reilly, C.M., McKenna, T.J., McKone, E.F., Gallagher, C.G., Androgens, exercise capacity, and muscle function in cystic fibrosis. Chest 134 (2008), 1258–1264.
33. Arikan, H., Yatar, I., Calik-Kutukcu, E., Aribas, Z., Saglam, M., Vardar-Yagli, N., et al. A comparison of respiratory and peripheral muscle strength, functional exercise capacity, activities of daily living and physical fitness in patients with cystic fibrosis and healthy subjects. Res Dev Disabil 45-46 (2015), 147–156.
34. Sahlberg, M.E., Svantesson, U., Thomas, E.M., Strandvik, B., Muscular strength and function in patients with cystic fibrosis. Chest 127 (2005), 1587–1592.
35. Vallier, J.M., Gruet, M., Mely, L., Pensini, M., Brisswalter, J., Neuromuscular fatigue after maximal exercise in patients with cystic fibrosis. J Electromyogr Kinesiol 21 (2011), 242–248.
36. McKone, E.F., Barry, S.C., Fitzgerald, M.X., Gallagher, C.G., Role of arterial hypoxemia and pulmonary mechanics in exercise limitation in adults with cystic fibrosis. J Appl Physiol 99 (2005), 1012–1018.
37. Rand, S., Prasad, S.A., Exercise as part of a cystic fibrosis therapeutic routine. Expert Rev Respir Med 6 (2012), 341–351.
38. Saynor, Z.L., Barker, A.R., Oades, P.J., Williams, C.A., Impaired aerobic function in patients with cystic fibrosis during ramp exercise. Med Sci Sports Exerc 46 (2014), 2271–2278.
39. Saynor, Z.L., Barker, A.R., Oades, P.J., Williams, C.A., Impaired pulmonary V O2 kinetics in cystic fibrosis depend on exercise intensity. Med Sci Sports Exerc, 2016, 10.1249/MSS.0000000000001004.
40. Werkman, M., Jeneson, J., Helders, P., Arets, B., van der Ent, K., Velthuis, B., et al. Exercise oxidative skeletal muscle metabolism in adolescents with cystic fibrosis. Exp Physiol 101 (2016), 421–431.
41. Rosenthal, M., Narang, I., Edwards, L., Bush, A., Non-invasive assessment of exercise performance in children with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis: is there a CF specific muscle defect?. Pediatr Pulmonol 44 (2009), 222–230.
42. Van Iterson, E.H., Wheatley, C.M., Baker, S.E., Morgan, W.J., Snyder, E.M., The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis. Heart Lung 45 (2016), 283–290.
43. Hebestreit, H., Arets, H.G., Aurora, P., Boas, S., Cerny, F., Hulzebos, E.H., et al. Statement on exercise testing in cystic fibrosis. Respiration 90 (2015), 332–351.
44. Coronell, C., Orozco-Levi, M., Mendez, R., Ramirez-Sarmiento, A., Galdiz, J.B., Gea, J., Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J 24 (2004), 129–136.
45. Evans, R.A., Kaplovitch, E., Beauchamp, M.K., Dolmage, T.E., Goldstein, R.S., Gillies, C.L., et al. Is quadriceps endurance reduced in COPD?: a systematic review. Chest 147 (2015), 673–684.
46. Gruet, M., Vallier, J.M., Mely, L., Brisswalter, J., Long term reliability of EMG measurements in adults with cystic fibrosis. J Electromyogr Kinesiol 20 (2010), 305–312.
47. Gosker, H.R., Zeegers, M.P., Wouters, E.F., Schols, A.M., Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 62 (2007), 944–949.
48. Bachasson, D., Millet, G.Y., Decorte, N., Wuyam, B., Levy, P., Verges, S., Quadriceps function assessment using an incremental test and magnetic neurostimulation: a reliability study. J Electromyogr Kinesiol 23 (2013), 649–658.
49. Gruet, M., Brisswalter, J., Mely, L., Vallier, J.M., Use of the peak heart rate reached during six-minute walk test to predict individualized training intensity in patients with cystic fibrosis: validity and reliability. Arch Phys Med Rehabil 91 (2010), 602–607.
50. Gruet, M., Brisswalter, J., Mely, L., Vallier, J.M., Clinical utility of the oxygen uptake efficiency slope in cystic fibrosis patients. J Cyst Fibros 9 (2010), 307–313.
51. Moorcroft, A.J., Dodd, M.E., Morris, J., Webb, A.K., Symptoms, lactate and exercise limitation at peak cycle ergometry in adults with cystic fibrosis. Eur Respir J 25 (2005), 1050–1056.
52. Orenstein, D.M., Nixon, P.A., Ross, E.A., Kaplan, R.M., The quality of well-being in cystic fibrosis. Chest 95 (1989), 344–347.
53. Perez, M., Groeneveld, I.F., Santana-Sosa, E., Fiuza-Luces, C., Gonzalez-Saiz, L., Villa-Asensi, J.R., et al. Aerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis. Pediatr Pulmonol 49 (2014), 641–649.
54. Martin, C., Chapron, J., Hubert, D., Kanaan, R., Honore, I., Paillasseur, J.L., et al. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med 107 (2013), 1881–1887.
55. Moorcroft, A.J., Dodd, M.E., Webb, A.K., Exercise testing and prognosis in adult cystic fibrosis. Thorax 52 (1997), 291–293.
56. Dodd, J.D., Barry, S.C., Gallagher, C.G., Respiratory factors do not limit maximal symptom-limited exercise in patients with mild cystic fibrosis lung disease. Respir Physiol Neurobiol 152 (2006), 176–185.
57. Pastre, J., Prevotat, A., Tardif, C., Langlois, C., Duhamel, A., Wallaert, B., Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC Pulm Med, 14, 2014, 74.
58. Perpati, G., Nanas, S., Pouliou, E., Dionyssopoulou, V., Stefanatou, E., Armeniakou, E., et al. Resting respiratory variables and exercise capacity in adult patients with cystic fibrosis. Respir Med 104 (2010), 1444–1449.
59. Orenstein, D.M., Nixon, P.A., Exercise performance and breathing patterns in cystic fibrosis: male-female differences and influence of resting pulmonary function. Pediatr Pulmonol 10 (1991), 101–105.
60. Killian, K.J., Leblanc, P., Martin, D.H., Summers, E., Jones, N.L., Campbell, E.J., Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 146 (1992), 935–940.
61. Quon, B.S., Wilkie, S.S., Molgat-Seon, Y., Schaeffer, M.R., Ramsook, A.H., Wilcox, P.G., et al. Cardiorespiratory and sensory responses to exercise in adults with mild cystic fibrosis. J Appl Physiol (1985) 119 (2015), 1289–1296.
62. Dodd, J.D., Barry, S.C., Daly, L.E., Gallagher, C.G., Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. J Cyst Fibros 4 (2005), 101–105.
63. Oelberg, D.A., Systrom, D.M., Markowitz, D.H., Zorb, S.L., Wright, C., Wain, J.C., et al. Exercise performance in cystic fibrosis before and after bilateral lung transplantation. J Heart Lung Transplant 17 (1998), 1104–1112.
64. Shah, A.R., Gozal, D., Keens, T.G., Determinants of aerobic and anaerobic exercise performance in cystic fibrosis. Am J Respir Crit Care Med 157 (1998), 1145–1150.
65. Boas, S.R., Joswiak, M.L., Nixon, P.A., Fulton, J.A., Orenstein, D.M., Factors limiting anaerobic performance in adolescent males with cystic fibrosis. Med Sci Sports Exerc 28 (1996), 291–298.
66. Lands, L.C., Heigenhauser, G.J., Jones, N.L., Analysis of factors limiting maximal exercise performance in cystic fibrosis. Clin Sci (Lond) 83 (1992), 391–397.
67. Cabrera, M.E., Lough, M.D., Doershuk, C.F., deRivera, G.A., Anaerobic performance assessed by the Wingate test in patients with cystic fibrosis. Pediatr Exerc Sci 5 (1993), 78–87.
68. Klijn, P.H., Terheggen-Lagro, S.W., Van Der Ent, C.K., Van Der Net, J., Kimpen, J.L., Helders, P.J., Anaerobic exercise in pediatric cystic fibrosis. Pediatr Pulmonol 36 (2003), 223–229.
69. Tattersall, R., Walshaw, M.J., Posture and cystic fibrosis. J R Soc Med 96:Suppl. 43 (2003), 18–22.
70. Penafortes, J.T., Guimaraes, F.S., Moco, V.J., Almeida, V.P., Dias, R.F., Lopes, A.J., Association among posture, lung function and functional capacity in cystic fibrosis. Rev Port Pneumol 19 (2013), 1–6.
71. Rawo, T., Trams, M., Michalski, P., Sands, D., Postural defects in children with cystic fibrosis — preliminary report. Dev Period Med 19 (2015), 114–119.
72. Lima, T.R., Guimaraes, F.S., Sa Ferreira, A., Penafortes, J.T., Almeida, V.P., Lopes, A.J., Correlation between posture, balance control, and peripheral muscle function in adults with cystic fibrosis. Physiother Theory Pract 30 (2014), 79–84.
73. Schindel, C.S., Hommerding, P.X., Melo, D.A., Baptista, R.R., Marostica, P.J., Donadio, M.V., Physical exercise recommendations improve postural changes found in children and adolescents with cystic fibrosis: a randomized controlled trial. J Pediatr 166 (2015), 710–716 [e2].
74. Thin, A.G., Linnane, S.J., McKone, E.F., Freaney, R., FitzGerald, M.X., Gallagher, C.G., et al. Use of the gas exchange threshold to noninvasively determine the lactate threshold in patients with cystic fibrosis. Chest 121 (2002), 1761–1770.
75. Maltais, F., Jobin, J., Sullivan, M.J., Bernard, S., Whittom, F., Killian, K.J., et al. Metabolic and hemodynamic responses of lower limb during exercise in patients with COPD. J Appl Physiol (1985) 84 (1998), 1573–1580.
76. Meyer, T., Faude, O., Scharhag, J., Urhausen, A., Kindermann, W., Is lactic acidosis a cause of exercise induced hyperventilation at the respiratory compensation point?. Br J Sports Med 38 (2004), 622–625.
77. Sharma, R., Florea, V.G., Bolger, A.P., Doehner, W., Florea, N.D., Coats, A.J., et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 56 (2001), 746–750.
78. Rehn, T.A., Munkvik, M., Lunde, P.K., Sjaastad, I., Sejersted, O.M., Intrinsic skeletal muscle alterations in chronic heart failure patients: a disease-specific myopathy or a result of deconditioning?. Heart Fail Rev 17 (2012), 421–436.
79. Savi, D., Quattrucci, S., Internullo, M., De Biase, R.V., Calverley, P.M., Palange, P., Measuring habitual physical activity in adults with cystic fibrosis. Respir Med 107 (2013), 1888–1894.
80. Nixon, P.A., Orenstein, D.M., Kelsey, S.F., Habitual physical activity in children and adolescents with cystic fibrosis. Med Sci Sports Exerc 33 (2001), 30–35.
81. Selvadurai, H.C., Blimkie, C.J., Cooper, P.J., Mellis, C.M., Van Asperen, P.P., Gender differences in habitual activity in children with cystic fibrosis. Arch Dis Child 89 (2004), 928–933.
82. Aznar, S., Gallardo, C., Fiuza-Luces, C., Santana-Sosa, E., Lopez-Mojares, L.M., Santalla, A., et al. Levels of moderate—vigorous physical activity are low in Spanish children with cystic fibrosis: a comparison with healthy controls. J Cyst Fibros 13 (2014), 335–340.
83. Britto, M.T., Garrett, J.M., Konrad, T.R., Majure, J.M., Leigh, M.W., Comparison of physical activity in adolescents with cystic fibrosis versus age-matched controls. Pediatr Pulmonol 30 (2000), 86–91.
84. Wells, G.D., Wilkes, D.L., Schneiderman, J.E., Rayner, T., Elmi, M., Selvadurai, H., et al. Skeletal muscle metabolism in cystic fibrosis and primary ciliary dyskinesia. Pediatr Res 69 (2011), 40–45.
85. Avesani, C.M., Carrero, J.J., Axelsson, J., Qureshi, A.R., Lindholm, B., Stenvinkel, P., Inflammation and wasting in chronic kidney disease: partners in crime. Kidney Int 70 (2006), S8–S13.
86. Couillard, A., Prefaut, C., From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J 26 (2005), 703–719.
87. Ionescu, A.A., Nixon, L.S., Evans, W.D., Stone, M.D., Lewis-Jenkins, V., Chatham, K., et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med 162 (2000), 789–794.
88. van de Weert-van Leeuwen, P.B., Hulzebos, H.J., Werkman, M.S., Michel, S., Vijftigschild, L.A., van Meegen, M.A., et al. Chronic inflammation and infection associate with a lower exercise training response in cystic fibrosis adolescents. Respir Med 108 (2014), 445–452.
89. Takabatake, N., Nakamura, H., Abe, S., Inoue, S., Hino, T., Saito, H., et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000), 1179–1184.
90. Galli, F., Battistoni, A., Gambari, R., Pompella, A., Bragonzi, A., Pilolli, F., et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta 2012 (1822), 690–713.
91. Urquhart, D.S., Montgomery, H., Jaffe, A., Assessment of hypoxia in children with cystic fibrosis. Arch Dis Child 90 (2005), 1138–1143.
92. Lezo, A., Biasi, F., Massarenti, P., Calabrese, R., Poli, G., Santini, B., et al. Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels?. J Cyst Fibros 12 (2013), 35–41.
93. Laursen, E.M., Juul, A., Lanng, S., Hoiby, N., Koch, C., Muller, J., et al. Diminished concentrations of insulin-like growth factor I in cystic fibrosis. Arch Dis Child 72 (1995), 494–497.
94. Ciro, D., Padoan, R., Blau, H., Marostica, A., Fuoti, M., Volpi, S., et al. Growth retardation and reduced growth hormone secretion in cystic fibrosis. Clinical observations from three CF centers. J Cyst Fibros 12 (2013), 165–169.
95. Sermet-Gaudelus, I., Souberbielle, J.C., Azhar, I., Ruiz, J.C., Magnine, P., Colomb, V., et al. Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients. Arch Dis Child 88 (2003), 956–961.
96. Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001), 1704–1708.
97. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004), 399–412.
98. Bodine, S.C., Baehr, L.M., Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am J Physiol Endocrinol Metab 307 (2014), E469–E484.
99. Smerieri, A., Montanini, L., Maiuri, L., Bernasconi, S., Street, M.E., FOXO1 content is reduced in cystic fibrosis and increases with IGF-I treatment. Int J Mol Sci 15 (2014), 18000–18022.
100. Wieboldt, J., Atallah, L., Kelly, J.L., Shrikrishna, D., Gyi, K.M., Lo, B., et al. Effect of acute exacerbations on skeletal muscle strength and physical activity in cystic fibrosis. J Cyst Fibros 11 (2012), 209–215.
101. Horsley, A.R., Davies, J.C., Gray, R.D., Macleod, K.A., Donovan, J., Aziz, Z.A., et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 68 (2013), 532–539.
102. Burtin, C., Van Remoortel, H., Vrijsen, B., Langer, D., Colpaert, K., Gosselink, R., et al. Impact of exacerbations of cystic fibrosis on muscle strength. Respir Res, 14, 2013, 46.
103. Ionescu, A.A., Mickleborough, T.D., Bolton, C.E., Lindley, M.R., Nixon, L.S., Dunseath, G., et al. The systemic inflammatory response to exercise in adults with cystic fibrosis. J Cyst Fibros 5 (2006), 105–112.
104. van de Weert-van Leeuwen, P.B., Arets, H.G., van der Ent, C.K., Beekman, J.M., Infection, inflammation and exercise in cystic fibrosis. Respir Res, 14, 2013, 32.
105. Selvadurai, H.C., Blimkie, C.J., Meyers, N., Mellis, C.M., Cooper, P.J., Van Asperen, P.P., Randomized controlled study of in-hospital exercise training programs in children with cystic fibrosis. Pediatr Pulmonol 33 (2002), 194–200.
106. Schakman, O., Kalista, S., Barbe, C., Loumaye, A., Thissen, J.P., Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 45 (2013), 2163–2172.
107. Barry, S.C., Gallagher, C.G., Corticosteroids and skeletal muscle function in cystic fibrosis. J Appl Physiol 95 (2003), 1379–1384.
108. Engelen, M.P.K.J., Com, G., Deutz, N.E.P., Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis. Curr Opin Clin Nutr Metab Care 17 (2014), 515–520.
109. Stallings, V.A., Tomezsko, J.L., Schall, J.I., Mascarenhas, M.R., Stettler, N., Scanlin, T.F., et al. Adolescent development and energy expenditure in females with cystic fibrosis. Clin Nutr 24 (2005), 737–745.
110. Hamilton, B., Vitamin D and human skeletal muscle. Scand J Med Sci Sports 20 (2010), 182–190.
111. Sexauer, W.P., Hadeh, A., Ohman-Strickland, P.A., Zanni, R.L., Varlotta, L., Holsclaw, D., et al. Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. J Cyst Fibros 14 (2015), 497–506.
112. Donovan, D.S. Jr., Papadopoulos, A., Staron, R.B., Addesso, V., Schulman, L., McGregor, C., et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 157 (1998), 1892–1899.
113. Sheikh, S., Gemma, S., Patel, A., Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab 33 (2015), 180–185.
114. Lancellotti, L., D'Orazio, C., Mastella, G., Mazzi, G., Lippi, U., Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr 155 (1996), 281–285.
115. Woestenenk, J.W., Broos, N., Stellato, R.K., Arets, H.G., van der Ent, C.K., Houwen, R.H., Vitamin E intake, alpha-tocopherol levels and pulmonary function in children and adolescents with cystic fibrosis. Br J Nutr 113 (2015), 1096–1101.
116. Darby, C.W., Davidson, A.G., Desai, I.D., Muscular performance in cystic fibrosis patients and its relation to vitamin E. Arch Dis Child 48 (1973), 72–75.
117. Levin, S., Gordon, M.H., Nitowsky, H.M., Goldman, C., Di Sant'Agnese, P., Gordon, H.H., Studies of tocopherol deficiency in infants and children. VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics 27 (1961), 578–588.
118. Oudshoorn, J.H., Klijn, P.H., Hofman, Z., Voorbij, H.A., van der Ent, C.K., Berger, R., et al. Dietary supplementation with multiple micronutrients: no beneficial effects in pediatric cystic fibrosis patients. J Cyst Fibros 6 (2007), 35–40.
119. Mador, M.J., Deniz, O., Aggarwal, A., Kufel, T.J., Quadriceps fatigability after single muscle exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168 (2003), 102–108.
120. Millet, G.Y., Martin, V., Martin, A., Verges, S., Electrical stimulation for testing neuromuscular function: from sport to pathology. Eur J Appl Physiol 111 (2011), 2489–2500.
121. Li, C., Ramjeesingh, M., Wang, W., Garami, E., Hewryk, M., Lee, D., et al. ATPase activity of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 271 (1996), 28463–28468.
122. Cheung, J.C., Kim Chiaw, P., Pasyk, S., Bear, C.E., Molecular basis for the ATPase activity of CFTR. Arch Biochem Biophys 476 (2008), 95–100.
123. Valdivieso, A.G., Santa-Coloma, T.A., CFTR activity and mitochondrial function. Redox Biol 1 (2013), 190–202.
124. Place, N., Bruton, J.D., Westerblad, H., Mechanisms of fatigue induced by isometric contractions in exercising humans and in mouse isolated single muscle fibres. Clin Exp Pharmacol Physiol 36 (2009), 334–339.
125. de Meer, K., Jeneson, J.A., Gulmans, V.A., van der Laag, J., Berger, R., Efficiency of oxidative work performance of skeletal muscle in patients with cystic fibrosis. Thorax 50 (1995), 980–983.
126. Erickson, M.L., Seigler, N., McKie, K.T., McCully, K.K., Harris, R.A., Skeletal muscle oxidative capacity in patients with cystic fibrosis. Exp Physiol 100 (2015), 545–552.
127. Rodriguez-Miguelez, P., Thomas, J., Seigler, N., Crandall, R., McKie, K.T., Forseen, C., et al. Evidence of microvascular dysfunction in patients with cystic fibrosis. Am J Physiol Heart Circ Physiol 310 (2016), H1479–H1485.
128. Pierini, D., Bryan, N.S., Nitric oxide availability as a marker of oxidative stress. Methods Mol Biol 1208 (2015), 63–71.
129. Couillard, A., Maltais, F., Saey, D., Debigare, R., Michaud, A., Koechlin, C., et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 (2003), 1664–1669.
130. Koechlin, C., Couillard, A., Simar, D., Cristol, J.P., Bellet, H., Hayot, M., et al. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease?. Am J Respir Crit Care Med 169 (2004), 1022–1027.
131. Decorte, N., Gruet, M., Camara, B., Quetant, S., Mely, L., Vallier, J.M., et al. Absence of calf muscle metabolism alterations in active cystic fibrosis adults with mild to moderate lung disease. J Cyst Fibros 16 (2017), 98–106.
132. Gruet, M., Temesi, J., Rupp, T., Levy, P., Millet, G.Y., Verges, S., Stimulation of the motor cortex and corticospinal tract to assess human muscle fatigue. Neuroscience 231 (2013), 384–399.
133. Dodd, J.W., Chung, A.W., van den Broek, M.D., Barrick, T.R., Charlton, R.A., Jones, P.W., Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med 186 (2012), 240–245.
134. Alexandre, F., Heraud, N., Oliver, N., Varray, A., Cortical implication in lower voluntary muscle force production in non-hypoxemic COPD patients. PLoS One, 9, 2014, e100961.
135. Gomez-Pinilla, F., Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 9 (2008), 568–578.
136. Guo, Y., Su, M., McNutt, M.A., Gu, J., Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain. J Histochem Cytochem 57 (2009), 1113–1120.
137. Tanaka, M., Watanabe, Y., Supraspinal regulation of physical fatigue. Neurosci Biobehav Rev 36 (2012), 727–734.
138. Yan, Z., Stewart, Z.A., Sinn, P.L., Olsen, J.C., Hu, J., McCray, P.B. Jr., et al. Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy. Hum Gene Ther Clin Dev 26 (2015), 38–49.
139. Welsh, M.J., Rogers, C.S., Stoltz, D.A., Meyerholz, D.K., Prather, R.S., Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc 120 (2009), 149–162.
140. Ruf, K., Winkler, B., Hebestreit, A., Gruber, W., Hebestreit, H., Risks associated with exercise testing and sports participation in cystic fibrosis. J Cyst Fibros 9 (2010), 339–345.
141. Radtke, T., Nolan, S.J., Hebestreit, H., Kriemler, S., Physical exercise training for cystic fibrosis. Cochrane Database Syst Rev, 6, 2015, CD002768.
142. Santana-Sosa, E., Gonzalez-Saiz, L., Groeneveld, I.F., Villa-Asensi, J.R., Barrio Gomez de Aguero, M.I., Fleck, S.J., et al. Benefits of combining inspiratory muscle with ‘whole muscle’ training in children with cystic fibrosis: a randomised controlled trial. Br J Sports Med 48 (2014), 1513–1517.
143. Santana Sosa, E., Groeneveld, I.F., Gonzalez-Saiz, L., Lopez-Mojares, L.M., Villa-Asensi, J.R., Barrio Gonzalez, M.I., et al. Intrahospital weight and aerobic training in children with cystic fibrosis: a randomized controlled trial. Med Sci Sports Exerc 44 (2012), 2–11.
144. Rovedder, P.M.E., Flores, J., Ziegler, B., Casarotto, F., Jaques, P., Barreto, S.S.M., et al. Exercise programme in patients with cystic fibrosis: a randomized controlled trial. Respir Med 108 (2014), 1134–1140.
145. Beaudoin, N., Bouvet, G.F., Coriati, A., Rabasa-Lhoret, R., Berthiaume, Y., Combined exercise training improves glycemic control in adult with cystic fibrosis. Med Sci Sports Exerc, 2016, 10.1249/MSS.0000000000001104.
146. Klijn, P.H., Oudshoorn, A., van der Ent, C.K., van der Net, J., Kimpen, J.L., Helders, P.J., Effects of anaerobic training in children with cystic fibrosis: a randomized controlled study. Chest 125 (2004), 1299–1305.
147. Swisher, A.K., Hebestreit, H., Mejia-Downs, A., Lowman, J.D., Gruber, W., Nippins, M., et al. Exercise and habitual physical activity for people with cystic fibrosis: expert consensus, evidence-based guide for advising patients. Cardiopulm Phys Ther J 26 (2015), 85–98.
148. Sillen, M.J., Franssen, F.M., Gosker, H.R., Wouters, E.F., Spruit, M.A., Metabolic and structural changes in lower-limb skeletal muscle following neuromuscular electrical stimulation: a systematic review. PLoS One, 8, 2013, e69391.
149. Vivodtzev, I., Decorte, N., Wuyam, B., Gonnet, N., Durieu, I., Levy, P., et al. Benefits of neuromuscular electrical stimulation prior to endurance training in patients with cystic fibrosis and severe pulmonary dysfunction. Chest 143 (2013), 485–493.
150. Stalvey, M.S., Anbar, R.D., Konstan, M.W., Jacobs, J.R., Bakker, B., Lippe, B., et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol 47 (2012), 252–263.
151. Braegger, C.P., Schlattner, U., Wallimann, T., Utiger, A., Frank, F., Schaefer, B., et al. Effects of creatine supplementation in cystic fibrosis: results of a pilot study. J Cyst Fibros 2 (2003), 177–182.
152. Boyle, M.P., Bell, S.C., Konstan, M.W., McColley, S.A., Rowe, S.M., Rietschel, E., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
153. Saynor, Z.L., Barker, A.R., Oades, P.J., Williams, C.A., The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective. Pediatr Phys Ther 26 (2014), 454–461.
154. McKenna, M.J., Medved, I., Goodman, C.A., Brown, M.J., Bjorksten, A.R., Murphy, K.T., et al. N-acetylcysteine attenuates the decline in muscle Na +,K +-pump activity and delays fatigue during prolonged exercise in humans. J Physiol 576 (2006), 279–288.
155. Medved, I., Brown, M.J., Bjorksten, A.R., Murphy, K.T., Petersen, A.C., Sostaric, S., et al. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J Appl Physiol (1985) 97 (2004), 1477–1485.
156. Nash, E.F., Stephenson, A., Ratjen, F., Tullis, E., Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev, 2009, CD007168.
157. 2 + sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol, 2016, 10.1113/JP273248.
158. Shefner, J., Cedarbaum, J.M., Cudkowicz, M.E., Maragakis, N., Lee, J., Jones, D., et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13 (2012), 430–438.
159. Russell, A.J., Hartman, J.J., Hinken, A.C., Muci, A.R., Kawas, R., Driscoll, L., et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med 18 (2012), 452–455.
160. Plant, B.J., Goss, C.H., Plant, W.D., Bell, S.C., Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med 1 (2013), 164–174.
161. Bohannon, R.W., Bubela, D.J., Wang, Y.C., Magasi, S.R., Gershon, R.C., Adequacy of belt-stabilized testing of knee extension strength. J Strength Cond Res 25 (2011), 1963–1967.
162. Bachasson, D., Villiot-Danger, E., Verges, S., Hayot, M., Perez, T., Chambellan, A., et al. Maximal isometric voluntary quadriceps strength assessment in COPD. Rev Mal Respir 31 (2014), 765–770.
163. Mier, A., Redington, A., Brophy, C., Hodson, M., Green, M., Respiratory muscle function in cystic fibrosis. Thorax 45 (1990), 750–752.
164. Stein, L., Pacht, C., Junge, S., Kaeding, T.S., Kuck, M., Maassen, N., et al. Skeletal muscle function in young patients with cystic fibrosis. Pediatr Exerc Sci 28 (2016), 364–373.
165. Gruet, M., Peyré-Tartaruga, L.A., Mely, L., Vallier, J.M., The 1-minute sit-to-stand test in adults with cystic fibrosis: correlations with cardiopulmonary exercise test, 6-minute walk test, and quadriceps strength. Respir Care, 2016, 10.4187/respcare.04821.
166. de Jong, W., van Aalderen, W.M., Kraan, J., Koeter, G.H., van der Schans, C.P., Skeletal muscle strength in patients with cystic fibrosis. Physiother Theory Pract 17 (2001), 23–28.